Introduction: Despite the introduction of novel agents, such as thalidomide, lenalidomide and bortezomib, multiple myeloma (MM) remains an incurable disease and new therapies are needed. mAbs are a new promising anticancer treatment option.Areas covered: This review will focus on mAbs that are currently under evaluation in Phase II and III clinical trials, as single agent and in combination with established treatment options.Expert opinion: mAbs are a new strategy against MM, and they have demonstrated encouraging results in preclinical models. mAbs have a relatively benign side-effect profile and work synergistically with traditional chemotherapies and with immunomodulatory drugs and proteasome inhibitors. © 2014 Informa UK, Ltd.

Monoclonal antibodies currently in Phase II and III trials for multiple myeloma

Donato F.
First
;
Gay F.;Bringhen S.
;
Troia R.;Palumbo A.
Last
2014-01-01

Abstract

Introduction: Despite the introduction of novel agents, such as thalidomide, lenalidomide and bortezomib, multiple myeloma (MM) remains an incurable disease and new therapies are needed. mAbs are a new promising anticancer treatment option.Areas covered: This review will focus on mAbs that are currently under evaluation in Phase II and III clinical trials, as single agent and in combination with established treatment options.Expert opinion: mAbs are a new strategy against MM, and they have demonstrated encouraging results in preclinical models. mAbs have a relatively benign side-effect profile and work synergistically with traditional chemotherapies and with immunomodulatory drugs and proteasome inhibitors. © 2014 Informa UK, Ltd.
2014
14
8
1127
1144
https://www.tandfonline.com/doi/abs/10.1517/14712598.2014.908848?journalCode=iebt20
https://doi.org/10.1517/14712598.2014.908848
Antibodies; Monoclonal; Multiple myeloma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Tumor Microenvironment
Donato F.; Gay F.; Bringhen S.; Troia R.; Palumbo A.
File in questo prodotto:
File Dimensione Formato  
[PUBLISHED Vsn.] Donato et al - 2014 - Monoclonal antibodies currently in Phase II and III trials.pdf

Accesso riservato

Descrizione: [PUBLISHED Vsn.] Donato et al - 2014 -
Tipo di file: PDF EDITORIALE
Dimensione 551.93 kB
Formato Adobe PDF
551.93 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1769446
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 10
social impact